化合物简介
Beloranib is a former drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and its clinical development was led by Zafgen. Drug development for the product was halted in 2016.
基本信息
英文名称：[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
英文别名：[(3R,6R,7S,8S)-7-methoxy-8-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-2-oxaspiro[2.5]octan-6-yl] (E)-3-[4-(2-dimethylaminoethyloxy)phenyl]prop-2-enoate;
(3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate;
Beloranib;
UNII-FI471K8BU6;
O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol;
CAS号：251111-30-5
分子式：C29H41NO6
分子量：499.63900
精确质量：499.29300
PSA：73.06000
LogP：4.25980
